The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody

Biochemical and Biophysical Research Communications

Volumn 318, Issue 2, 2004, Pages 507-513

  Lu, Dan ^a   Jimenez, Xenia ^a   Witte, Larry ^a   Zhu, Zhenping ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antibody engineering; Bispecific antibody; Diabody; Domain orientation; EGFR; IGFR; Variable domain

Indexed keywords

ANTIGEN; BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; RECOMBINANT ANTIBODY; RECOMBINANT HUMAN BISPECIFIC DIABODY; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG STABILITY; GENE CONSTRUCT; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SERUM; STATISTICAL SIGNIFICANCE; TEMPERATURE;

ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; DRUG STABILITY; ESCHERICHIA COLI; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; KINETICS; PROTEIN ENGINEERING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, SOMATOMEDIN; RECOMBINANT PROTEINS;

EID: 2142662111     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.04.060     Document Type: Article

References (22)

1. Cao Y., Suresh M.R. Bispecific antibodies as novel bioconjugates. Bioconjug. Chem. 9:1998;635-644
2. van Spriel A.B., van Ojik H.H., van de Winkel J.G.J. Immunotherapeutic perspective for bispecific antibodies. Immunol. Today. 21:2000;391-397
3. Segal D.M., Weiner G.J., Weiner L.M. Introduction: bispecific antibodies. J. Immunol. Methods. 248:2001;1-6
4. Lu D., Kotanides H., Jimenez J., Zhou Q., Persaud K., Bohlen P., Witte L., Zhu Z. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J. Immunol. Methods. 230:1999;159-171
5. Lu D., Jimenez X., Zhang H., Wu Y., Bohlen P., Witte L., Zhu Z. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res. 61:2001;7002-7008
6. Lu D., Zhang H., Ludwig D., Persaud A., Jimenez X., Burtrum D., Balderes P., Liu M., Bohlen P., Witte L., Zhu Z. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J. Biol. Chem. 279:2004;2856-2865
7. Carter P., Ridgway J., Zhu Z. Toward the production of bispecific antibody fragments for clinical applications. J. Hematother. 4:1995;463-470
8. Plückthun A., Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology. 3:1997;83-105
9. Todorovska A., Roovers R.C., Dolezal O., Kortt A.A., Hoogenboom H.R., Hudson P.J. Design and application of diabodies, triabodies, and tetrabodies for cancer targeting. J. Immunol. Methods. 248:2001;47-66
10. Carter P. Bispecific human IgG by design. J. Immunol. Methods. 248:2001;7-15
11. Holliger P., Prospero T., Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA. 90:1993;6444-6448
12. Whitlow M., Filpula D., Rollence M.L., Feng S.L., Wood J.F. Multivalent Fvs: Characterization of single-chain Fv oligomers and preparation of a bispecific Fv. Protein Eng. 7:1994;1017-1026
13. Zhu Z., Zapata G., Shalaby M.R., Snedecor B., Chen H., Carter P. High level secretion of a humanized bispecific diabody from Escherichia coli. Bio/technology (NY). 14:1996;192-196
14. Xiong D., Xu Y., Liu H., Peng H., Shao X., Lai Z., Fan D., Yang M., Han J., Xie Y., Yang C., Zhu Z. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20. × anti-CD3 bispecific diabody Cancer Lett. 177:2002;29-39
15. Gao Y., Xiong D., Yang M., Liu H., Peng H., Shao X., Xu Y., Xu C., Fan D., Qin L., Yang C., Zhu Z. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein. × anti-CD3 diabody Leukemia. 18:2004;513-520
16. De Haard H.J., va Neer N., Reurs A., Hufton S.E., Roovers R.C., Henderikx P., de Bruine A.P., Arends J.-W., Hoogenboom H.R. A large non-immunized human Fab fragment phage library that permit rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274:1999;18218-18230
17. Burtrum D., Zhu Z., Lu D., Anderson D.M., Prewett M., Pereira D.S., Bassi R., Abdullah R., Hooper A.T., Koo H., Jimenez X., Johnson D., Apblett R., Kussie P., Bohlen P., Witte L., Hicklin D.J., Ludwig D.L. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 63:2003;8912-8921
18. Zhu Z., Rockwell P., Lu D., Kotanides H., Pytowski B., Hicklin D.J., Bohlen P., Witte L. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res. 58:1998;3209-3214
19. Perisic O., Webb P.A., Holliger P., Winter G., Williams R.L. Crystal structure of a diabody, a bivalent antibody fragment. Structure. 2:1994;1217-1226
20. Carmichael J.A., Power B.E., Garrett T.P., Yazaki P.J., Shively J.E., Raubischek A.A., Wu A.M., Hudson P.J. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J. Mol. Biol. 326:2003;341-351
21. Kipriyanov S.M., Moldenhauer G., Braunagel M., Reusch U., Cochlovius B., Le Gall F., Kouprianova O.A., Von der Lieth C.W., Little M. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J. Mol. Biol. 330:2003;99-111
22. Lu D., Shen J., Vil M.D., Zhang H., Jimenez X., Bohlen P., Witte L., Zhu Z. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J. Biol. Chem. 278:2003;43496-43507